Were Bruce C. Cozadd’s JAZZ share sales under a Rule 10b5-1 plan?

Yes, the filing states the transactions were executed under a Rule 10b5-1 trading plan adopted by Bruce C. Cozadd. Such plans allow insiders to schedule trades in advance, providing a structured framework for selling shares over time under predetermined instructions.

Bruce Cozadd sells 6,000 Jazz Pharmaceuticals (JAZZ) shares in 10b5-1 plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals director Bruce C. Cozadd reported selling a total of 6,000 ordinary shares of JAZZ in open-market transactions on March 3, 2026. The sales occurred in three blocks at weighted average prices of $186.0853, $186.7340 and $187.8444, executed under a Rule 10b5-1 trading plan. Following these planned sales, Cozadd directly owns 405,796 ordinary shares of Jazz Pharmaceuticals.

Insider Trade Summary

Net Seller: 6,000 shares

Net Sell 3 txns

Insider COZADD BRUCE C

Role Director

Sold 6,000 shs ($1.12M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,159	$186.0853	$588K
Sale	Ordinary Shares	2,608	$186.734	$487K
Sale	Ordinary Shares	233	$187.8444	$44K

Holdings After Transaction: Ordinary Shares — 405,796 shares (Direct)

Footnotes (4)

F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.500 to $187.4693. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $187.7783 to $188.1678 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/04/2026 - 04:24 PM

FAQ

What insider transaction did JAZZ director Bruce C. Cozadd report?

Bruce C. Cozadd reported selling 6,000 Jazz Pharmaceuticals ordinary shares in open-market transactions. The sales were split into three trades on March 3, 2026, at weighted average prices between $186.0853 and $187.8444, and were executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices were Bruce C. Cozadd’s JAZZ shares sold?

The reported Jazz Pharmaceuticals share sales occurred at weighted average prices of $186.0853, $186.7340 and $187.8444. Footnotes explain these represent multiple trades within price ranges from $185.500 to $188.1678, with full trade details available upon request from the company or regulators.

How many Jazz Pharmaceuticals shares does Bruce C. Cozadd now hold?

After the reported sales, Bruce C. Cozadd directly holds 405,796 ordinary shares of Jazz Pharmaceuticals. This post-transaction ownership figure reflects the completion of the three open-market sale trades disclosed for March 3, 2026, under his Rule 10b5-1 trading plan.

How many total JAZZ shares did Bruce C. Cozadd sell in this filing?

The Form 4 shows that Bruce C. Cozadd sold 6,000 ordinary shares of Jazz Pharmaceuticals. This total comes from three separate non-derivative open-market sale transactions of 3,159 shares, 2,608 shares and 233 shares, all executed on March 3, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	03/03/2026		S⁽¹⁾		3,159	D	$186.0853⁽²⁾	408,637	D
Ordinary Shares	03/03/2026		S⁽¹⁾		2,608	D	$186.734⁽³⁾	406,029	D
Ordinary Shares	03/03/2026		S⁽¹⁾		233	D	$187.8444⁽⁴⁾	405,796	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.500 to $187.4693. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $187.7783 to $188.1678 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR